According to a recent press release from Respira Therapeutics, their investigational treatment for pulmonary arterial hypertension (PAH), RT234, has just been administered to the first patient in a phase 2b…
Welcome to Study of the Week from Patient Worthy. In this segment, we select a study we posted about from the previous week that we think is of particular interest…
The American Association for Cancer Research (AACR) Annual Meeting took place from April 8th until the 13th, with lots of interesting data and innovations presented by some of the leaders…
One of the largest problems that stands in the way of rare disease research is funding. It can be difficult to raise the enormous amounts of money needed to plan,…
Two years ago, China approved ensartinib as a second-line therapy for those with ALK+ non-small cell lung cancer (NSCLC). There have been advances over time. Now, according to a late…
A team of researchers from Yale School of Public Health, including Dr. Peter Krause, Dr. Durland Fish, Demerise Johnston, and others, have published a study in the journal Clinical Infectious Diseases documenting a…
Nelson Ambrogio had always looked up to his older brother, Daniel. He has many positive memories of growing up with him. They both shared a passion for soccer, and Nelson…
In the Phase 3 KEYNOTE-522 clinical trial, researchers found that pembrolizumab was effective in treating patients with triple-negative breast cancer (TNBC). According to Medical XPress, researchers wanted to determine whether…
According to a recent article from WFMZ+, the FDA has recently approved Regeneron's supplemental Biologics License Application (sBLA) for Dupixent, granting it priority review. Dupixent, also known by the generic…
Did you know that an estimated 50% of those with lupus have neuropsychiatric symptoms, or symptoms which impact their mental and psychological health and functioning? For example, some people with…
On April 6, 2022, biotechnology company Dialectic Therapeutics announced via press release that its therapeutic candidate DT2216, designed for relapsed or refractory (R/R) cutaneous T-cell lymphoma (CTCL) or peripheral T-cell…
In the United States, Orphan Drug designation is granted by the FDA to drugs or biologics intended to treat, prevent, or diagnose rare diseases or conditions. “Rare” is defined as…
According to a recent article, a study has found that denosumab therapy leads to patients with osteoporosis having a higher risk of getting osteonecrosis of the jaw in comparison to…
According to a recent article, investigators have proposed a checklist that will aid in determining the strength of potential gene-disease relationships for rare disease. The Need It has already…
April 15, 2022 marks the 9th annual International Pompe Day, designed to help raise awareness and education around Pompe disease. The slogan of International Pompe Day is "Together We…
According to a recent press release, the FDA has recently granted approval to Vijoice - also known under the generic name alpelisib - for the treatment of PIK3CA-related overgrowth spectrum…
A study recently published in the journal ESMO Open has documented new biomarkers which may be able to predict efficacy outcomes of antiangiogenic therapies (such as surufatinib) in patients diagnosed with neuroendocrine…
A recent study titled "Effect of FT218, a Once-Nightly Sodium Oxybate Formulation, on Disrupted Nighttime Sleep in Patients With Narcolepsy: Results From the Randomized Phase 3 REST-ON Trial," was published…
According to a recent article, last week was Porphyria Awareness Week, a week dedicated to recognizing and uniting those who are a part of the porphyria community. Porphyria Porphyria is…
If you have not heard of craniosynostosis, it is understandable, as the disorder affects only one infant out of approximately 2500. A recent article published in the Washington News…
The Timothy Syndrome Alliance (TSA) has just announced that they will be collaborating with Pulse Infoframe to create a patient registry. This registry will increase our understanding of the CACNA1C…
Adverse events (AEs) are unexpected medical issues that arise upon treatment. Now, this is a very broad term, and it can be broken down into more specific categories depending on…
In a Phase 3 clinical trial, researchers evaluated I/ONTAK (also known as E7777) as a potential therapeutic option for persistent or recurrent cutaneous T-cell lymphoma (CTCL). According to Targeted Oncology,…
CureDuchenne is one of Patient Worthy's partner organizations. Patient Worthy partners with a variety of rare disease and patient-oriented non-profits in order to collaborate and help promote one another's activities.…
The American Academy of Neurology (AAN) 2022 Annual Meeting is held from April 2nd until the 7th in Seattle, with its virtual counterpart happening on April 24th to the 26th.…
© Copyright 2024 Patient Worthy
Sign Up With a Patient Worthy Account and Share Your Rare Story
- OR -
Make a difference, share your experiences and get paid. Opt-in and join Patient Worthy's panel for paid opportunities such as surveys, market research, patient advisory panels and more.
- OR -
Make a difference, share your experiences and get paid. Opt-in and join Patient Worthy's panel for paid opportunities such as surveys, market research, patient advisory panels and more.
